Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
1. To compare the efficacy of CP-690,550 in doses of 5 mg BID and 10 mg BID versus placebo for the treatment of signs and symptoms of RA in patients with active RA who have had an inadequate response to a DMARD (traditional or biologic), as measured by ACR20 response rates at Month 6. 2. To compare physical function status of patients after administration of CP-690,550 in doses of 5 mg BID or 10 mg BID versus placebo using the HAQ-DI at Month 3 compared to baseline in patients with active RA on background traditional DMARDs. 3. To compare the rate of achieving DAS 28-4(ESR) <2.6 at Month 6 in patients with active RA after administration of CP-690,550, in doses of 5 mg BID and 10 mg BID versus placebo. 4. To evaluate the safety and tolerability of CP-690,550 in doses of 5 mg BID and 10 mg BID versus placebo in patients with active RA on background traditional DMARDs.
Critère d'inclusion
- Rheumatoid Arthritis